(MedPage Today) — Adding a GLP-1 receptor agonist was not associated with a lower likelihood of discontinuing existing basal insulin therapy among veterans with type 2 diabetes compared with other glucose-lowering agents, a target emulation trial…
Source: MedPage Today — Headlines
